Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 6/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916207 | 1.00 | PDE4D (0.48) | PDE4DPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL917329 | 0.96 | PDE4D (0.51) | PDE4DPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL917925 | 0.96 | PDE4D (0.43) | PDE4DPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL916681 | 0.90 | PIK3CD (0.39) | PDE4DPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3676661 | 0.89 | PDE4D (0.37) | PDE4DTBK1PDE4BPDE4APDE4C | |
| SCHEMBL3680467 | 0.89 | PDE4D (0.37) | PDE4DTBK1PDE4BPDE4APDE4C | |
| SCHEMBL4974075 | 0.88 | PIK3CD (0.41) | PDE4DPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL917203 | 0.88 | PIK3CD (0.41) | PDE4DPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL918060 | 0.88 | PIK3CD (0.40) | PDE4DPIK3CDPIK3CAPIK3CBTBK1 | |
| SCHEMBL917973 | 0.87 | PDE4D (0.41) | PDE4DTBK1PDE4BHRH3PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | claimed |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | PDE4A, PDE4B, PDE4C | PDE4D 6/4885PIK3CD 117/4885PIK3CA 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.